Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2023

Open Access 01-12-2023 | Metastasis | Research

Impacts of ovarian preservation on the prognosis of neuroendocrine cervical carcinoma: a retrospective analysis based on machine learning

Authors: Xuesong Xiang, Yunqiang Zhang, Keqin Hua, Jingxin Ding

Published in: World Journal of Surgical Oncology | Issue 1/2023

Login to get access

Abstract

Background

Neuroendocrine cervical carcinoma (NECC) is a rare but aggressive malignancy with younger patients compared to other common histology types. This study aimed to evaluate the impacts of ovarian preservation (OP) on the prognosis of NECC through machine learning.

Methods

Between 2013 and 2021, 116 NECC patients with a median age of 46 years received OP or bilateral salpingo-oophorectomy (BSO) and were enrolled in a retrospective analysis with a median follow-up of 41 months. The prognosis was estimated using Kaplan–Meier analysis. Random forest, LASSO, stepwise, and optimum subset prognostic models were constructed in training cohort (randomly selected 70 patients) and tested in 46 patients through receiver operator curves. Risk factors for ovarian metastasis were identified through univariate and multivariate regression analyses. All data processing was carried out in R 4.2.0 software.

Results

Among 116 patients, 30 (25.9%) received OP and showed no significantly different OS compared with BSO group (p = 0.072) and got better DFS (p = 0.038). After construction of machine learning models, the safety of OP was validated in lower prognostic risk group (p > 0.05). In patients ≤ 46 years, no impacts of OP were shown for DFS (p = 0.58) or OS (p = 0.67), and OP had no impact on DFS in different relapse risk population (p > 0.05). In BSO group, regression analyses showed that later stage, para-aortic LNM, and parametrial involvement were associated with ovarian metastasis (p < 0.05).

Conclusions

Preserving ovaries had no significant impact on prognosis in patients with NECC. OP should be considered cautiously in patients with ovarian metastasis risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019;29:986–95.CrossRefPubMed Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019;29:986–95.CrossRefPubMed
2.
go back to reference Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol. 2007;34:57–63.CrossRefPubMed Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol. 2007;34:57–63.CrossRefPubMed
3.
go back to reference Chen J, Sun Y, Chen L, Zang L, Lin C, Lu Y, Lin L, Lin A, Dan H, Chen Y, He H. Prognostic factors and treatment of neuroendocrine tumors of the uterine cervix based on the FIGO 2018 staging system: a single-institution study of 172 patients. PeerJ. 2021;9: e11563.CrossRefPubMedPubMedCentral Chen J, Sun Y, Chen L, Zang L, Lin C, Lu Y, Lin L, Lin A, Dan H, Chen Y, He H. Prognostic factors and treatment of neuroendocrine tumors of the uterine cervix based on the FIGO 2018 staging system: a single-institution study of 172 patients. PeerJ. 2021;9: e11563.CrossRefPubMedPubMedCentral
4.
go back to reference Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M, Sakamoto A, Kaku T, Nakanishi T, Hasumi Y, Iwata T, Baba T, et al. Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol. 2018;148:139–46.CrossRefPubMed Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M, Sakamoto A, Kaku T, Nakanishi T, Hasumi Y, Iwata T, Baba T, et al. Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol. 2018;148:139–46.CrossRefPubMed
5.
go back to reference Yuan L, Jiang H, Lu Y, Guo SW, Liu X. Prognostic factors of surgically treated early-stage small cell neuroendocrine carcinoma of the cervix. Int J Gynecol Cancer. 2015;25:1315–21.CrossRefPubMed Yuan L, Jiang H, Lu Y, Guo SW, Liu X. Prognostic factors of surgically treated early-stage small cell neuroendocrine carcinoma of the cervix. Int J Gynecol Cancer. 2015;25:1315–21.CrossRefPubMed
6.
go back to reference Lee SW, Nam JH, Kim DY, Kim JH, Kim KR, Kim YM, Kim YT. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer. 2010;20:411–6.CrossRefPubMed Lee SW, Nam JH, Kim DY, Kim JH, Kim KR, Kim YM, Kim YT. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer. 2010;20:411–6.CrossRefPubMed
7.
go back to reference Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93:27–33.CrossRefPubMed Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93:27–33.CrossRefPubMed
8.
go back to reference Georgescu TA, Bohiltea RE, Munteanu O, Furtunescu F, Lisievici AC, Grigoriu C, Gherghiceanu F, Vlădăreanu EM, Berceanu C, Ducu I, Iordache AM: Emerging therapeutic concepts and latest diagnostic advancements regarding neuroendocrine tumors of the gynecologic tract. Medicina (Kaunas). 2021;57(12):1338. Georgescu TA, Bohiltea RE, Munteanu O, Furtunescu F, Lisievici AC, Grigoriu C, Gherghiceanu F, Vlădăreanu EM, Berceanu C, Ducu I, Iordache AM: Emerging therapeutic concepts and latest diagnostic advancements regarding neuroendocrine tumors of the gynecologic tract. Medicina (Kaunas). 2021;57(12):1338.
9.
go back to reference Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011;122:190–8.CrossRefPubMed Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011;122:190–8.CrossRefPubMed
10.
go back to reference McCusker ME, Coté TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol. 2003;88:333–9.CrossRefPubMed McCusker ME, Coté TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol. 2003;88:333–9.CrossRefPubMed
11.
go back to reference Singh S, Redline R, Resnick KE. Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy. Gynecol Oncol Rep. 2015;13:5–7.CrossRefPubMedPubMedCentral Singh S, Redline R, Resnick KE. Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy. Gynecol Oncol Rep. 2015;13:5–7.CrossRefPubMedPubMedCentral
12.
go back to reference Buonomo B, Multinu F, Casarin J, Betella I, Zanagnolo V, Aletti G, Peccatori F. Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review. Int J Gynecol Cancer. 2021;31:360–70.CrossRefPubMed Buonomo B, Multinu F, Casarin J, Betella I, Zanagnolo V, Aletti G, Peccatori F. Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review. Int J Gynecol Cancer. 2021;31:360–70.CrossRefPubMed
13.
go back to reference Ngamcherttakul V, Ruengkhachorn I. Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA. Asian Pac J Cancer Prev. 2012;13:4525–9.CrossRefPubMed Ngamcherttakul V, Ruengkhachorn I. Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA. Asian Pac J Cancer Prev. 2012;13:4525–9.CrossRefPubMed
14.
go back to reference Chen J, Wang R, Zhang B, Lin X, Wei J, Jia Y, Yin Y, Ye S, Zhu T, Chen G, et al. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis. Am J Obstet Gynecol. 2016;215:460.e461-460.e413.CrossRef Chen J, Wang R, Zhang B, Lin X, Wei J, Jia Y, Yin Y, Ye S, Zhu T, Chen G, et al. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis. Am J Obstet Gynecol. 2016;215:460.e461-460.e413.CrossRef
15.
go back to reference Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89:281–7.CrossRefPubMed Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89:281–7.CrossRefPubMed
16.
go back to reference Chen J, Han Y, Shi W, Yan X, Shi Y, Yang Y, Gao H, Li Y. Ovarian tissue bank for fertility preservation and anti-menopause hormone replacement. Front Endocrinol (Lausanne). 2022;13: 950297.CrossRefPubMed Chen J, Han Y, Shi W, Yan X, Shi Y, Yang Y, Gao H, Li Y. Ovarian tissue bank for fertility preservation and anti-menopause hormone replacement. Front Endocrinol (Lausanne). 2022;13: 950297.CrossRefPubMed
17.
go back to reference Pan M, Pan X, Zhou J, Wang J, Qi Q, Wang L. Update on hormone therapy for the management of postmenopausal women. Biosci Trends. 2022;16:46–57.CrossRefPubMed Pan M, Pan X, Zhou J, Wang J, Qi Q, Wang L. Update on hormone therapy for the management of postmenopausal women. Biosci Trends. 2022;16:46–57.CrossRefPubMed
18.
go back to reference Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRefPubMed
19.
go back to reference Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. 2012;120:595–603.CrossRefPubMedPubMedCentral Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. 2012;120:595–603.CrossRefPubMedPubMedCentral
20.
go back to reference Kim J, Bhupathiraju SN, Harrington LB, Hagan KA, Lindström S, Manson JE, Kraft P, Kabrhel C. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause. 2022;29:293–303.CrossRefPubMedPubMedCentral Kim J, Bhupathiraju SN, Harrington LB, Hagan KA, Lindström S, Manson JE, Kraft P, Kabrhel C. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause. 2022;29:293–303.CrossRefPubMedPubMedCentral
21.
go back to reference Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, Liou WS, Hsu ST, Ou YC, Yeh LS, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012;48:1484–94.CrossRefPubMed Wang KL, Chang TC, Jung SM, Chen CH, Cheng YM, Wu HH, Liou WS, Hsu ST, Ou YC, Yeh LS, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012;48:1484–94.CrossRefPubMed
22.
go back to reference Tian WJ, Zhang MQ, Shui RH. Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. Oncol Lett. 2012;3:125–30.CrossRefPubMed Tian WJ, Zhang MQ, Shui RH. Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. Oncol Lett. 2012;3:125–30.CrossRefPubMed
23.
go back to reference Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19:321–6.CrossRefPubMed Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19:321–6.CrossRefPubMed
24.
go back to reference Lan-Fang L, Hai-Yan S, Zuo-Ming Y, Jian-Qing Z, Ya-Qing C. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases. Eur J Gynaecol Oncol. 2012;33:68–73.PubMed Lan-Fang L, Hai-Yan S, Zuo-Ming Y, Jian-Qing Z, Ya-Qing C. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases. Eur J Gynaecol Oncol. 2012;33:68–73.PubMed
25.
go back to reference Rajkumar S, Iyer R, Culora G, Lane G. Fertility sparing management of large cell neuroendocrine tumour of cervix: a case report & review of literature. Gynecol Oncol Rep. 2016;18:15–7.CrossRefPubMedPubMedCentral Rajkumar S, Iyer R, Culora G, Lane G. Fertility sparing management of large cell neuroendocrine tumour of cervix: a case report & review of literature. Gynecol Oncol Rep. 2016;18:15–7.CrossRefPubMedPubMedCentral
26.
go back to reference Wu PY, Cheng YM, New GH, Chou CY, Chiang CT, Tsai HW, Huang YF. Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix. BMC Womens Health. 2017;17:56.CrossRefPubMedPubMedCentral Wu PY, Cheng YM, New GH, Chou CY, Chiang CT, Tsai HW, Huang YF. Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix. BMC Womens Health. 2017;17:56.CrossRefPubMedPubMedCentral
27.
go back to reference Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer. 2003;97:568–74.CrossRefPubMed Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer. 2003;97:568–74.CrossRefPubMed
28.
go back to reference Zivanovic O, Leitao MM Jr, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Chi DS, Abu-Rustum NR, Aghajanian C. Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009;112:590–3.CrossRefPubMed Zivanovic O, Leitao MM Jr, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Chi DS, Abu-Rustum NR, Aghajanian C. Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009;112:590–3.CrossRefPubMed
29.
go back to reference Landoni F, Zanagnolo V, Lovato-Diaz L, Maneo A, Rossi R, Gadducci A, Cosio S, Maggino T, Sartori E, Tisi C, et al. Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer. 2007;17:623–8.CrossRefPubMed Landoni F, Zanagnolo V, Lovato-Diaz L, Maneo A, Rossi R, Gadducci A, Cosio S, Maggino T, Sartori E, Tisi C, et al. Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer. 2007;17:623–8.CrossRefPubMed
30.
go back to reference Zhang Y, Li L, Wang Z, Huang Y, Luo S, Peng Y, Li N, He Y, Li C, Zhang K, et al. Preferred method of therapy for patients with early-stage high-grade neuroendocrine carcinoma of the cervix. Am J Cancer Res. 2021;11:4595–606.PubMedPubMedCentral Zhang Y, Li L, Wang Z, Huang Y, Luo S, Peng Y, Li N, He Y, Li C, Zhang K, et al. Preferred method of therapy for patients with early-stage high-grade neuroendocrine carcinoma of the cervix. Am J Cancer Res. 2021;11:4595–606.PubMedPubMedCentral
31.
go back to reference Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111:1394–402.CrossRefPubMed Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111:1394–402.CrossRefPubMed
32.
go back to reference Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21:3495–501.CrossRefPubMed Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21:3495–501.CrossRefPubMed
33.
go back to reference Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24:S102–8.CrossRefPubMed Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24:S102–8.CrossRefPubMed
Metadata
Title
Impacts of ovarian preservation on the prognosis of neuroendocrine cervical carcinoma: a retrospective analysis based on machine learning
Authors
Xuesong Xiang
Yunqiang Zhang
Keqin Hua
Jingxin Ding
Publication date
01-12-2023
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2023
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-023-03014-9

Other articles of this Issue 1/2023

World Journal of Surgical Oncology 1/2023 Go to the issue